Clinical Trial Update: A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial update for FX-909 in patients with advanced urothelial carcinoma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• FX-909

Snippet

Sponsor: Flare Therapeutics Inc. | Conditions: Advanced Urothelial Carcinoma, Oral Drug Administration | Phase 1 | Status: RECRUITING